Via this multicenter phase II trial, researchers sought to ascertain the efficacy and safety of bevacizumab plus mFOLFOX6 for patients with advanced colorectal liver metastases (CRLMs) harboring mutant-type KRAS.

• Researchers performed evaluation of surgical indication every 4 cycles of bevacizumab plus mFOLFOX6 among patients with advanced CRLMs (tumor number of ≥5 and/or technically unresectable) harboring mutant-type KRAS.

• Among 29 registered patients from six centers, complete and partial responses were observed at the rates of 0% and 62.1%, respectively.

• There were 19 and 1 patient who received R0 and R1 resections, respectively (R0 resection rate: 65.5%).

• Overall findings suggest achievement of a high R0 resection rate for advanced CRLMs harboring mutant-type KRAS by using bevacizumab plus mFOLFOX6, resulting in favorable survival.